Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 5:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–58 of 58 matching trials from the live ClinicalTrials.gov search.
Conditions
Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disease, Acute Leukemia, Multiple Myeloma
Interventions
Rituximab, Cyclosporine, Allogenic stem cell transplant (ASCT), Conditioning Chemotherapy, TMS, FLAG, EPOCH-F, Alemtuzumab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 74 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Anemia, Aplastic
Interventions
Cyclophosphamide,Campath IH and TBI
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
Up to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Leukemia, Myelodysplasia, Chronic Myelomonocytic Leukemia
Interventions
Ruxolitinib, Myeloablative conditioning regimen, Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Tacrolimus
Drug · Procedure
Lead sponsor
Hannah Choe, MD
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • Boston, Massachusetts • Columbus, Ohio
Conditions
Transplantation, Liver
Interventions
Campath-1H and Tacrolimus
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
alemtuzumab, graft-versus-tumor induction therapy, rituximab, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, allogeneic bone marrow transplantation
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
40 Years to 72 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Transplant; Failure, Kidney
Interventions
Alemtuzumab, Daclizumab, Thymoglobulin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Miami, Florida
Conditions
Inherited Metabolic Storage Diseases
Interventions
CAMPATH-1H, Anti-CD45, FK506, Fludarabine
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
2
States / cities
Houston, Texas
Conditions
Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
alemtuzumab, busulfan, cyclophosphamide, methotrexate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
2
States / cities
Seattle, Washington
Conditions
Sickle Cell Disease
Interventions
Hematopoietic Stem Cell Transplantation
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
3 Years to 19 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
19
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 16 more
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
alemtuzumab, therapeutic allogeneic lymphocytes, fludarabine phosphate, melphalan, tacrolimus, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut